Sir -The report by Owens et al. (1993) on the interleukin-2 receptor in ovarian cancer raises a number of questions.
The interleukin-2 receptor that the authors refer to is more correctly described as the soluble interleukin-2 receptor a. Furthermore, in their introduction, the authors seem to be unaware of IL-2Ry (Kamio et al., 1992; Takeshita et al., 1992) . It is not correct to state that both the 55 kDa and 75 kDa components bind IL-2 with low affinity. The current hypothesis is that IL-2Rx binds IL-2 with low affinity, but this receptor is not expressed on normal human cells as the only IL-2 receptor. The intermediate-affinity receptor, formerly designated the 75 kDa receptor, is now known to be a heterodimeric structure of IL-2RP and IL-2Ry (Taniguchi & Minami, 1993) .
The authors state that 'To date IL-2R has been evaluated extensively in haematological malignancies, but seldom in ovarian cancer.' We first published results on the serum and ascitic levels of sIL-2Ra, and correlated these with CA-125 levels (Barton et al., 1993a) . The values for serum sIL-2Ra obtained by Owens et al. (1993) are similar to those we had reported. Our study showed that the ascitic levels of sIL-2Ra exceeded the serum levels, an observation in keeping with the known tendency of ovarian cancer to remain confined to the peritoneal cavity.
Finally, we have also studied the effect of surgery on serum sIL-2Ra levels in gynaecological cancers (Barton et al., 1993b 
